New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012

Five Star Equities Provides Stock Research on Affymax and DARA Biosciences

Marketwired

NEW YORK, NY--(Marketwire - Mar 13, 2013) - Programs developed by the U.S. Food and Drug Administration to speed up the approval process has been a major driver for growth within the Biotech Industry. In 2012, FDA drug approvals totaled a 15-year high of 39, over the past decade drug approvals has averaged roughly 23 a year, according to a recent Bloomberg article. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Affymax, Inc. (NASDAQ: AFFY) and DARA Biosciences Inc. (NASDAQ: DARA).

Access to the full company reports can be found at:

www.FiveStarEquities.com/AFFY
www.FiveStarEquities.com/DARA

The FDA's new "breakthrough" product designation allows new drugs to win approval after just a single round of testing, instead of the usual three. A total of three promising experimental medicines have been assigned the new status so far, while an additional 18 drugs have applied. The new designation follows three other programs -- Fast Track, Priority Review and Accelerated Approval -- each of which were designed to help bring crucial new drugs to market in a shorter amount of time.

"A breakthrough drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Affymax, our mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. Shares of the company fell sharply last month after announcing a nationwide voluntary recall of all lots of OMONTYS (peginesatide) Injection.

DARA Biosciences is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company in November submitted an Orphan Drug Application to the FDA for KRN5500. KRN5500's Fast Track status was approved in 2011.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer

View Comments (0)